Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis

Rheumatology

Volumn 44, Issue 1, 2005, Pages 74-79

  Doležalová, Pavla ^a   Krijt, J ^a   Chladek J ^a   Nemcova D ^a   Hoza, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adenosine; Juvenile arthritis; Methotrexate polyglutamates

Indexed keywords

ADENOSINE; AMINOPHYLLINE; CAFFEINE; FOLIC ACID; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; THEOPHYLLINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; ENZYME ASSAY; ERYTHROCYTE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LIQUID CHROMATOGRAPHY; LONG TERM CARE; MALE; NEUROTOXICITY; PRIORITY JOURNAL; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; VENOUS BLOOD;

ADENOSINE; ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; HUMANS; MALE; METHOTREXATE; POLYGLUTAMIC ACID; TREATMENT OUTCOME;

EID: 12344262977     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh401     Document Type: Article

References (42)

1. Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;5:266-73.
2. Cutolo M, Sulli A, Pizzorni C, Seriolo B. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729-35.
3. Hillson JL, Furst DE. Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Rheum Dis Clin North Am 1997;23:757-78.
4. Balis FM, Mirro J, Reaman GH et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988;6:1882-6.
5. Allegra CJ, Drake JC, Jolivet BA. Inhibition of phosphoribosylamino-imidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985; 82:4881-5.
6. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidised folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
7. Baggott JE, Morgan SL, Koopman WJ. The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion. Arthritis Rheum 1998;41: 1407-10.
8. Gruber HE, Hoffer ME, McAllister DR et al. Increased adenosine concentration in blood from ischaemic myocardium by AICA riboside: effects on flow, granulocytes and injury. Circulation 1989;80:1400-11.
9. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-56.
10. Morabito L, Montesinos MC, Schreibman DM et al. Methotrexate and sulphasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998;101:295-300.
11. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25:33-9.
12. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991;88:2441-5.
13. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
14. 3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-7.
15. Bernini J, Fort DW, Griener JC et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995;345:544-7.
16. Montesinos MC, Yap JS, Desai A et al. Reversal of the anti-inflammatory effects of methotrexate by the non-selective adenosine receptor antagonists theophylline and caffeine. Arthritis Rheum 2000; 43:656-63.
17. Baggott JE, Morgan SL, Sams WM, Linden J. Urinary adenosine and aminoimidazolcarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 1999;135:813-7.
18. Laghi Pasini F, Capecchi PL, Di Perri T. Adenosine plasma levels after low-dose methotrexate administration. J Rheumatol 1997;24:2492-3.
19. Petty RE, Southwood TR, Baum J et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991-4.
20. Giannini EH, Ruperto N, Ravelli A et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
21. Schroder H, Heinsvig EM. Enzymatic assay for methotrexate in erythrocytes. Scand J Clin Lab 1985;45:657-9.
22. Chládek J, Martínková J, Šimková M et al. Pharmacokinetics of low dose methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998; 53:437-44.
23. Smoleńska Z, Kaznovska Z, Zaróvny D et al. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology 1999;38:997-1002.
24. Gadangi P, Longaker M, Naime D et al. The anti-inflammatory mechanism of sulphasalazine is related to adenosine release at inflamed sites. J Immunol 1996;156:1937-41.
25. Albertioni F, Flato B, Seideman P et al. Methotrexate in juvenile rheumatoid arthritis-evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995;47:507-11.
26. Ravelli A, DiFuccia G, Molinar M et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 1993;20:1573-7.
27. Hendel J, Nyfors A. Pharmacokinetics of methotrexate in erythrocytes in psoriasis. Eur J Clin Pharmacol 1984;27:607.
28. Jundt JW, Browne BA, Fiocco GP et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9.
29. Schmiegelov K, Schroder H, Gustafsson G et al. Risk of relapse in childhood acute lymphoblastic leukaemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J Clin Oncol 1995;13:345-51.
30. Angelis-Stoforidis P, Vajda FJE, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313-20.
31. Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-90.
32. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003;62:4-9.
33. 2B receptor activation. J Exp Med 1998;8:1433-43.
34. Van Waeg G, Van den Berghe G. Purine catabolism in polymorpho-nuclear neutrophils. Phorbol myristate acetate-induced accumulation of adenosine owing to inactivation of extracellularly released adenosine deaminase. J Clin Invest 1991;87:305-12.
35. Barankiewicz J, Ronlov G, Jimenez R, Gruber HE. Selective adenosine release from human B but not T lymphoid cell line. J Biol Chem 1990;26:15738-43.
36. 1-adrenoceptor stimulation. Br J Pharmacol 1994;113:1203-8.
37. Kitakaze M, Masatsugu H, Morioka T et al. Attenuation of ecto-5′-nucleotidase activity and adenosine release in activated human polymorphonuclear leukocytes. Circul Res 1993;73:524-33.
38. Nakamachi Y, Koshiba M, Nakyawa T et al. Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthritis Rheum 2003;48:668-74.
39. Martin C, Leone M, Viviand X et al. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med 2000;28:3198-202.
40. Laghi Pasini F, Guideri F, Petersen C et al. Blunted increase in plasma adenosine levels following dipyridamole stress in dilated cardiomyopathy patients. J Int Med 2003;254:591-6.
41. Sottofattori E, Anzaldi M, Ottonello L. HPLC determination of adenosine in human synovial fluid. J Pharm Biomed Anal 2001; 24:1143-6.
42. Dawicki DD, Agarwal KC, Parks RJ. Adenosine metabolism in human whole blood: effects of nucleoside transport inhibitors and phosphate concentration. Biochem Pharmacol 1988;37:621-6.